Nanostructured Therapeutic Systems of PUFA'S for the Treatment of Glioblastoma Multiforme.

Glioblastoma multiforme (GBM) is the typical categories of the most common and aggressive brain tumors with high incidence more often in older adults. The etiology of GBM has not been fully elucidated. Clinically, GBM is characterized by highly proliferative activity in the glial cells, and its complete resection is impossible, and radiotherapy is not always efficient. GBM remain a therapeutic challenge in neuro-oncology because there is no treatment that achieves a significant improvement in survival. In this regard, the identification of newer drug therapy for the treatment of GBM is gaining popularity. However, the process of identifying new targets and development of new leads for screening suitable drug candidates require the investment of resources like time, money, and efforts. Thus, the use of PUFAs therapeutic moieties for such tumor treatment has yielded significant interest owing to their cost-effective availability, limited sideeffects, and insensitivity towards drug resistance. Nevertheless, implications of the nanostructured therapeutic systems in delivering the PUFAs can provide significant augmentation in their biopharmaceutical performance and antitumor activity over the existing synthetic drug therapy. Now a days various studies showed that polyunsaturated fatty acids especially glinolenic acid (GLA) have selective tumoricidal action especially against malignant gliomacells.The present, in this regard, endeavors to provide an insight into the applications of nanomedicines-loaded with PUFAs therapeutics for effective treatment of GBM and associated diseases.